AstraZeneca shares plunged 9% on Thursday after the company disclosed that a late-stage clinical trial for a heart drug failed to meet its primary endpoint. The U.K.'s largest drugmaker said the trial did not achieve the desired results, triggering a sharp sell-off in its stock.
The setback deals a blow to AstraZeneca's pipeline, as the heart drug had been viewed as a potential growth driver. Investors had been optimistic about the therapy's prospects, making the miss particularly disappointing. This failure could pressure the company to redirect resources to other programs.
The drugmaker did not provide specific details on the magnitude of the miss or implications for the program. Analysts will now scrutinize the full trial data for any silver linings or secondary benefits. The stock's 9% drop erased roughly £10 billion in market value.
Regulatory prospects for the drug now appear uncertain, potentially delaying or ending its path to market. Competitors in the cardiovascular space may gain a window of opportunity. AstraZeneca's broader portfolio, including its oncology franchise, may need to compensate for this loss.
Some analysts, however, caution that single trial failures do not always spell doom. They point to other drugmakers that have revived programs after refining their approach or identifying new uses for candidates.